Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic SignaturesASX:GSS -1.49% 3-Year ROIIC % is -1,625.74 as of Jun. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Genetic Signatures ranks worse than 98.04% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Genetic Signatures's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was -1,625.74%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Genetic Signatures's 3-Year ROIIC % or its related term are showing as below:
ASX:GSS's 3-Year ROIIC % is ranked worse than 98.04% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs ASX:GSS: -1625.74
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Genetic Signatures 3-Year ROIIC % Related Terms
Genetic Signatures 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Genetic Signatures's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:GSS vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Genetic Signatures's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Signatures 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Genetic Signatures's 3-Year ROIIC % falls into.
Genetic Signatures's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -18.481 (Jun. 2025) - 2.865 (Jun. 2022) )
/
( 20.405 (Jun. 2025) - 19.092 (Jun. 2022) )
=
-21.346
/
1.313
=
-1,625.74%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Genetic Signatures (ASX:GSS) has a 3-Year ROIIC % of -1,625.74 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genetic Signatures and its competitors. According to the industry distribution chart, Genetic Signatures ranks #200 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 98%.
Is Genetic Signatures' 3-Year ROIIC % too high?
Genetic Signatures' current 3-Year ROIIC % is -1,625.74. Based on the distribution chart, Genetic Signatures ranks #200 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Genetic Signatures' 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetic Signatures ranks #200 out of 204 companies for 3-Year ROIIC %. This places Genetic Signatures in the lower half of its industry. The industry median 3-Year ROIIC % is 0.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Genetic Signatures and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetic Signatures's current 3-Year ROIIC % is -1,625.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Signatures stock overvalued right now?
Based on GuruFocus' analysis, Genetic Signatures (ASX:GSS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.38, compared to a current price of A$0.07 — trading 82.6% below its estimated fair value. The current 3-Year ROIIC % is -1,625.74. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Genetic Signatures (ASX:GSS), the current 3-Year ROIIC % is -1,625.74 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genetic Signatures Ltd is a specialist molecular diagnostics company, specializing in syndromic multiplex real-time PCR testing. The company offers products for the routine detection of infectious diseases and pathogens. It has three operating segments based on regions: Asia Pacific, EMEA, and Americas. It generates the majority of its revenue from the Asia Pacific region. The group's operations are based in Australia, with sales and support teams in the UK, Germany, and the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:GSS has been successfully added to your 
